Douglass Winthrop Advisors LLC lifted its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 78.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 85,776 shares of the biopharmaceutical company's stock after acquiring an additional 37,653 shares during the period. Douglass Winthrop Advisors LLC's holdings in Pfizer were worth $2,276,000 at the end of the most recent quarter.
Other institutional investors have also added to or reduced their stakes in the company. Retirement Wealth Solutions LLC bought a new position in Pfizer in the fourth quarter valued at $26,000. Rialto Wealth Management LLC bought a new position in shares of Pfizer in the 4th quarter valued at about $26,000. Kohmann Bosshard Financial Services LLC acquired a new stake in shares of Pfizer in the fourth quarter valued at about $28,000. Noble Wealth Management PBC bought a new stake in Pfizer during the fourth quarter worth about $31,000. Finally, Curio Wealth LLC acquired a new position in Pfizer during the fourth quarter valued at approximately $32,000. 68.36% of the stock is owned by institutional investors.
Pfizer Price Performance
PFE stock traded down $0.15 during midday trading on Monday, reaching $26.13. The company had a trading volume of 37,863,216 shares, compared to its average volume of 36,651,022. The company has a market capitalization of $148.21 billion, a price-to-earnings ratio of 18.53, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. Pfizer Inc. has a 1-year low of $24.48 and a 1-year high of $31.54. The stock has a 50 day moving average price of $26.17 and a 200-day moving average price of $27.04.
Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping analysts' consensus estimates of $0.48 by $0.15. The company had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm's quarterly revenue was up 24.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.10 EPS. Equities research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.
Analyst Ratings Changes
A number of equities research analysts have recently issued reports on PFE shares. UBS Group dropped their price objective on Pfizer from $31.00 to $29.00 and set a "neutral" rating on the stock in a research note on Wednesday, January 8th. Truist Financial lowered their price objective on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a research note on Wednesday, December 18th. Citigroup reduced their price target on Pfizer from $30.00 to $29.00 and set a "neutral" rating for the company in a report on Tuesday, January 28th. Bank of America restated a "neutral" rating and issued a $29.00 price objective on shares of Pfizer in a research note on Tuesday, December 10th. Finally, Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, six have given a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $31.92.
Get Our Latest Research Report on Pfizer
Insider Buying and Selling at Pfizer
In other Pfizer news, Director Ronald E. Blaylock acquired 19,457 shares of the company's stock in a transaction that occurred on Thursday, February 13th. The stock was acquired at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the transaction, the director now directly owns 27,707 shares in the company, valued at $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 0.06% of the company's stock.
About Pfizer
(
Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
See Also
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
